Response to cancer therapy not only depends on genetic variation of genes involved in drug transport and metabolism (ADME), but drug efficacy and resistance mechanisms in cancer are multifactorial including features of the tumour and the tumour microenvironment. Here, especially -omics approaches enable better understanding of the underlying mechanisms and identification of genetic, epigenetic and metabolic patterns as potential biomarkers. Concentrating particularly on ADME processes for cancer drugs, our aim is to identify drug targets and related agents for translation into clinical application with a current focus on renal cancer. Additionally, the integration of Omics and pathological as well as clinical data requires the application of novel technologies and bioinformatics approaches.


Prof. Dr. Matthias Schwab
Head of the Institute
Go to profile
Dr. Elke Schaeffeler
Research Group Leader Integrative Omics Analyses and Cancer Therapy
Head of Molecular Analytics
Go to profile